GBT

Global Blood
NASDAQ

Real-time Quotes | Nasdaq Last Sale

71.12
+1.78
+2.57%
Closed 17:24 07/10 EDT
OPEN
69.52
PREV CLOSE
69.34
HIGH
72.46
LOW
68.77
VOLUME
764.03K
TURNOVER
--
52 WEEK HIGH
87.54
52 WEEK LOW
39.95
MARKET CAP
4.33B
P/E (TTM)
-14.5774
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 17 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average GBT stock price target is 108.31 with a high estimate of 150.00 and a low estimate of 60.00.

EPS

GBT News

More
GBT Announces New Employment Inducement Grants
GlobeNewswire · 4d ago
Global Blood Analyst Projects More Than 60% Upside On Receding Sickle Cell Drug Concerns
Shares of Global Blood Therapeutics Inc (NASDAQ: GBT) have materially underperformed the broader biotech group, rendering its valuation attractive, according to Goldman Sachs.
Benzinga · 07/01 19:22
Goldman Sachs Upgrades Global Blood Therapeutics to Buy, Raises Price Target to $103
Goldman Sachs analyst Paul Choi upgrades Global Blood Therapeutics (NASDAQ:GBT) from Neutral to Buy and raises the price target from $91 to $103.
Benzinga · 07/01 10:33
GBT Awards $250,000 in ACCEL Grants to Advance Access to Care for People Living with Sickle Cell Disease
For the second year, the ACCEL program has funded innovative programs that have the potential to deliver high-quality healthcare to people living with SCD. “The passion and innovation in the ACCEL grant proposals that we received this year gives us hope that
GlobeNewswire · 06/25 17:00
Global Blood to Seek Approval of Oxbryta in Europe for SCD
Zacks · 06/25 13:59
GBT Announces Plans to Seek Regulatory Approval for Oxbryta® (voxelotor) to Treat Sickle Cell Patients in Europe
GlobeNewswire · 06/24 13:30
Global Blood to file European application for Oxbryta for SCD anemia
Seeking Alpha - Article · 06/24 12:45
GBT Announces Plans To Seek Regulatory Approval For Oxbryta (voxelotor) To Treat Sickle Cell Patients In Europe
GBT Announces Plans to Seek Regulatory Approval for Oxbryta® (voxelotor) to Treat Sickle Cell Patients in Europe Intends to seek full marketing authorization for Oxbryta to treat hemolyticanemia in sickle cell
Benzinga · 06/24 12:32

Industry

Biotechnology & Medical Research
-0.39%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About GBT

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD). The Company is evaluating GBT440 in SCD in a Phase III clinical trial of GBT440 in adult and adolescent patients with SCD. GBT440 inhibits abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. The Company is also engaged in other research and development activities targeted towards hereditary angioedema (HAE). The Company's GBT440 is an investigational drug that increases hemoglobin's affinity for oxygen by binding to the alpha-chain of hemoglobin. GBT440 has been observed to keep a proportion of sickle hemoglobin (HbS), in its oxygenated state, where it cannot participate in polymerization.
More

Webull offers kinds of Global Blood Therapeutics Inc stock information, including NASDAQ:GBT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GBT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GBT stock methods without spending real money on the virtual paper trading platform.